Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Floxuridine in Locally Advanced Gastric or GEJ Adenocarcinoma
NCT00848783Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- May 2008
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of floxuridine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by NYU Langone Health. Primary endpoint: Recurrence-free Survival at 1 year. Started May 2008; status: terminated.
02
Drugs
floxuridine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00848783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848783.